Are you a runner? Please join our #Run4HepB team and make your miles matter at the NYC Marathon on Nov. 3! Learn more.

 

LiverCancerConnect

Liver Cancer Drug Watch

Compounds in Development for Liver Cancer

Updated May 2024

Drug Name 

Mechanism 

Company

Company Website

USA Status

Clinical Trial Website

Nexavar (Sorafenib) 

Raf/kit/ret kinase inhibitor

Bayer

nexavar-us.com

Approved

N.A.

Keytruda(Pembrolizumab)

PD-1 checkpoint inhibitor

Merck

keytruda.com

Approved for use after treatment with sorafenib (Nexavar)  N.A.
Opdivo (Nivolumab) + Yervoy (Ipilimumab) CTLA-4-blocking antibody + PD-1 checkpoint inhibitor Bristol-Myers Squibb  opdivo.com/advanced-hcc Approved for combination use after treatment with sorafenib (Nexavar) N.A.

Stivarga (Regorafenib) 

Raf/kit/ret kinase inhibitor

Bayer

stivarga.com

Approved

N.A.

Opdivo (Nivolumab) 

PD1 inhibitor

Bristol Myers-Squibb

opdivo.com

Approved

N.A.

Lenvima (Lenvatinib) 

VEGFR, PDGFR, FGFR, RET and c-Kit inhibitor

Eisai

lenvima.com

Approved

N.A.

Cabometyx (Cabozantinib) 

VEGFR inhibitor

Exelixis

cabometyx.com

Approved

N.A.

Tecentriq (Atezolizumab) + Avastin (Bevacizumab) 

PD-L1 monoclonal antibody/VEGFA inhibitor

Genentech

tecentriq.com

Approved

N.A.

Cyramza (Ramucirumab) 

VEGFR2 inhibitor

Eli Lilly and Co.

cyramza.com

Approved

N.A.

Imjudo (tremelimumab) 

CTLA-4

AstraZeneca 

astrazeneca.com 

Approved

N.A. 

Imfinzi (Durvalumab) + Tremelimumab (imjudo)

PD-L1/CTLA-4 monoclonal antibody

AstraZeneca

astrazeneca.com

Phase III

Clinical Trial

Cabozantinib + Opdivo (Nivolumab) ± Yervoy (Ipilimumab) 

MET inhibitor, PD1 inhibitor, CTLA-4-blocking antibody

Exelixis and Bristol-Myers Squibb

exelixis.com

Phase I/II

Clinical Trial

Atezolizumab + , Bevacizumab + or - Tiragolumab

 

Roche

roche.com

 Phase III Clinical Trial

 

Atezolizumab + Multi-Kinase Inhibitor vs. Multi-Kinase Inhibitor (Cabozantinib or Lenvatinib) alone 

 

Roche

roche.com

Phase II

Clinical Trial

Atezolizumab + Bevacizumab or Atezolizumab alone

 

Genentech

genentech.com  Phase II Clinical Trial

 

Combinations of Atezolizumab, Tiragolumab, Bevacizumab, Tobemstomig

 

Roche

roche.com

 Phase Ib/II Clinical Trial

Combinations of Atezolizumab, Tiragolumab, Bevacizumab, Tobemstomig, Tocilizumab, TPST-1120, ADG126

 

Roche

roche.com

 Phase Ib/II Clinical Trial

Cabozantinib + Tecentriq (Atezolizumab) vs. Nexavar (Sorafenib) 

MET inhibitor + PD-L1 monoclonal antibody vs. Raf/Mek/Erk inhibitor

Exelixis

exelixis.com

Phase III

Clinical Trial

Toripalamib + Lenvatinib

PD-1/VEGFR2, VEGFR3 antibody

Shanghai Junshi Bioscience Co.

 

Phase III

Clinical Trial

Nexavar (Sorafenib), as adjuvant 

Raf, KIT, FLT, RET, VEGFR, PDGFR inhibitor

Bayer

nexavar.com

Phase III

Study completed

Yiviva (YIV-906) + Sorafenib

Botanical

Yiviva Inc.

yiviva.com

Phase II

Clinical Trial

MTL-CEBPA + Sorafenib

CEBPA RNA Activator MiNA Therapeutics minatx.com

 

Phase II   Clinical Trial

 

Pembrolizumab + Nexavar (Sorafenib)

PD-1/VEGFRs, C-KIT, PDGFRB, RAF inhibitor

Roswell Park Cancer Institute and Merck Sharpe & Dohme Corp.

roswellpark.org

Phase Ib/II

Clinical Trial

Pembrolizumab + Lenvima (Lenvatinib)

PD-1/VEGFR2, VEGFR3 antibody

Eisai

lenvima.com

Phase III

Clinical Trial

Pembrolizumab + Lenvima (Lenvatinib) + TACE

 
 

PD-1/VEGFR2, VEGFR3 antibody

 
Eisai lenvima.com

 

 Phase III Clinical Trial

 

Cabozantinib + Opdivo (Nivolumab)

MET inhibitor, VEGFRs/PD-1 antibody

Exelixis and Bristol-Myers Squibb

exelixis.com

Phase II

Study completed (before resection)

Clinical Trial (with TACE)

ET140203 Artemis® T Cells  T-cell therapy Eureka Therapeutics eurekatherapeutics.com  Phase I/II

Clinical Trial (ARYA-1)

Clinical Trial (ARYA-2)

Stivarga (Regorafenib) + Pembrolizumab

VEGFRs, FGFRs, C-KIT, PDGFRs, RAF/PD-1 antibody

Bayer and Merck Sharpe & Dohme Corp.

stivarga.com

Phase II

Clinical Trial

Tremelimumab (Imjudo), Durvalumab (Imfinzi) +/- Lenvatinib (Lenvima) + TACE 

PL-L1, CTLA4, VEGF 

AstraZeneca

astrazeneca.com

Phase III

Clinical Trial

Durvalumab (Imfinzi) + Bevacizumab (Avastin)  + TACE

PL-L1, VEGF 

AstraZeneca

astrazeneca.com

Phase III Clinical Trial 

Durvalumab (Imfinzi) + Bevacizumab (Avastin) 

PL-L1, VEGF  AstraZeneca astrazeneca.com Phase III Clinical Trial

Nivolumab + Relatlimab + Bevacizumab

PD-1 small molecular inhibitor, LAG3 inhibitor, VEGF BMS bmsclinicaltrials.com Phase I/II Clinical Trial

Regorafenib + Pembrolizumab vs. TACE

VEGFRs, FGFRs, C-KIT, PDGFRs, RAF/PD-1 antibody Bayer stivarga.com Phase III Clinical Trial